← Leaderboards
Risha Irvin
Johns Hopkins University
$2,546,197
Attributed
$4,482,309
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,092,393 · 3
By mechanism
R01$3,872,225 · 1
P30$1,220,168 · 2
Top collaborators
- David L Thomas5 shared
- Denis Godwin Antoine1 shared
- Richard E Chaisson1 shared
- Nathan Alex Irvin1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Michael D Sweat$30,121,757
- Andrea L Cox$41,369,991
- Gregory M Lucas$25,457,285
- David L Thomas$44,227,388
- Carl A Latkin$38,006,118
Others in their field
Other Emerging Leaders on “Funding”
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lynn Briscoe · Leidos Biomedical Research, Inc.$295,272,057
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$251,636,500
Research focus
FundingHarm ReductionCommunitiesProgramsPublic HealthHepatitis CHiv/HcvHepatitis C VirusHiv InfectionsFutureDesignRaceContinuity Of Patient CareLearningLouisianaEpidemicCurative TreatmentsHepatitis C AcquisitionCostDatabasesHepatitis C AntibodiesEpidemiologyFlexibilityEconomic Impact
Grant awards (7)
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$736,715
R01 · FY2024 · DA · contact PI
The CFAR Diversity, Equity, and Inclusion Pathway Initiative to Support The Continued Development of Generation Tomorrow (JHU CFAR Supplement)$610,084
P30 · FY2024 · AI · contact PI
The CFAR Diversity, Equity, and Inclusion Pathway Initiative to Support The Continued Development of Generation Tomorrow (JHU CFAR Supplement)$610,084
P30 · FY2024 · AI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$759,561
R01 · FY2023 · DA · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$769,782
R01 · FY2022 · DA · contact PI
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$779,830
R01 · FY2021 · DA
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination$826,337
R01 · FY2020 · DA